OncoMatch/Clinical Trials/NCT06601296
Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
Is NCT06601296 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies IMSA101 for metastatic renal cell carcinoma ( mrcc).
Treatment: IMSA101 — To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Disease stage
Metastatic disease required
Lab requirements
Blood counts
adequate organ and marrow function within 14 days prior to study entry
Kidney function
adequate organ and marrow function within 14 days prior to study entry
Liver function
adequate organ and marrow function within 14 days prior to study entry
Patients must have adequate organ and marrow function within 14 days prior to study entry.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Texas Southwestern Medical Center · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify